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Summary  Atrial  ﬁbrillation  is  the  most  frequently  occurring  sustained  cardiac  arrhythmia
and is  associated  with  a  signiﬁcantly  increased  risk  of  thromboembolic  events  and  death.
We sought  to  compare  the  clinical  efﬁcacy  of  rate  and  rhythm  control  strategies  in  patients
with non-postoperative  atrial  ﬁbrillation.  We  searched  the  PubMed  database  and  the  Cochrane
Central Register  of  Controlled  Trials  for  randomized  controlled  trials  comparing  rate  versusDigitalis; rhythm control  in  patients  with  atrial  ﬁbrillation.  Studies  were  retrieved  and  we  analysed  major
Antiarrhythmia
agents;
Atrial  ﬁbrillation
clinical outcomes.  Risk  ratios  (RRs)  and  95%  conﬁdence  intervals  were  calculated  assuming
random effects  due  to  the  clinical  heterogeneity  of  the  study  populations.  Eight  randomized
controlled  trials  were  identiﬁed,  with  a  total  of  7499  patients  with  atrial  ﬁbrillation.  There
were no  signiﬁcant  differences  in  the  effects  of  rate  and  rhythm  control  on  any  outcome:
Abbreviations: AF, Atrial ﬁbrillation; AFFIRM, Atrial Fibrillation Follow-up Investigation of Rhythm Management study; AF-CHF, Atrial
ibrillation and Congestive Heart Failure study; CAFÉ-II, Controlled study of rate versus rhythm control in patients with chronic AF and heart
ailure; CI, Conﬁdence interval; HOT CAFÉ, How to Treat Chronic Atrial Fibrillation study; J-RHYTHM, Japanese Rhythm Management Trial
or Atrial Fibrillation; PIAF, Pharmacological Intervention in Atrial Fibrillation study; RACE, Rate Control versus Electrical Cardioversion for
ersistent Atrial Fibrillation study; RCT, Randomized controlled trial; RR, Risk ratio; STAF, Strategies of Treatment of Atrial Fibrillation study.
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all-cause  mortality  (RR:  0.95;  CI:  0.86—1.05),  cardiovascular  mortality  (RR:  0.99;  CI:
0.87—1.13), arrhythmic/sudden  death  (RR:  1.12;  CI:  0.91—1.38),  ischaemic  stroke  (RR:  0.89;
CI: 0.52—1.53),  systemic  embolism  (RR:  0.89;  CI:  0.69—1.14)  and  major  bleeding  (RR:  1.10;  CI:
0.89—1.36). Updated  data  pooled  from  a  large  population  of  patients  with  atrial  ﬁbrillation  sug-
gests that  rate  and  rhythm  control  strategies  have  similar  effects  on  major  clinical  outcomes.
Other factors,  including  individual  preferences,  comorbidities,  drug  tolerance  and  cost  issues,
should be  considered  when  choosing  the  approach  for  these  patients.
© 2011  Elsevier  Masson  SAS.  All  rights  reserved.
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Résumé  La  ﬁbrillation  atriale  est  l’arythmie  cardiaque  soutenue  la  plus  fréquente  et  est
associée avec  une  augmentation  du  risque  de  complication  thromboembolique  et  de  décès.
Notre objectif  a  été  de  comparer  l’efﬁcacité  clinique  des  stratégies  contrôles  du  rythme  ver-
sus contrôle  de  la  fréquence  cardiaque  chez  des  patients  en  ﬁbrillation  atriale  en  excluant  la
phase postopératoire.  Notre  recherche  a  été  centrée  sur  les  bases  de  données  PubMed  et  CEN-
TRAL, avec  les  mots  clés  « essais  randomisés  contrôlés  » comparant  les  stratégies  de  contrôle
de la  fréquence  du  rythme  cardiaque  chez  les  patients  en  ﬁbrillation  atriale.  Les  études  ont
été analysées  pour  ce  qui  concerne  les  évènements  cliniques  majeurs.  Le  risque  relatif  et  les
intervalles  de  conﬁance  à  95  %  ont  été  calculés,  en  retenant  l’hypothèse  d’effets  au  hasard  dus
à l’hétérogénéité  clinique  des  populations  incluses  dans  les  différentes  études.  Huit  essais  ran-
domisés contrôlés  ont  été  identiﬁés,  incluant  un  total  de  7499  patients  en  ﬁbrillation  atriale.  Il
n’y avait  pas  de  différence  signiﬁcative  entre  les  deux  stratégies  pour  ce  qui  concerne  le  taux
de mortalité  globale  (RR  :  0,95  ;  IC  95  %  :  0,86—1,05),  la  mortalité  cardiovasculaire  (RR  :  0,99  ;
IC 95  %  :  0,87—1,13),  la  mort  subite  ou  arythmique  (RR  :  1,12  ;  IC  95  %  :  0,91—1,38),  le  taux
d’accident  ischémique  cérébral  (RR  :  0,89  ;  IC  95  %  :  0,52—1,53),  d’embolie  systémique  (RR  :
0,89 ;  IC  95  %  :  0,69—1,14)  et  le  taux  de  saignement  majeur  (RR  :  1,10  ;  IC  95  %  :  0,89—1,36).
Cette méta-analyse,  mise  à  jour  des  précédentes,  basée  sur  une  population  importante  de
patients  en  ﬁbrillation  atriale  suggère  que  les  deux  stratégies:  contrôle  du  rythme  ou  de  la
fréquence cardiaque  dans  la  ﬁbrillation  atriale,  ont  des  effets  similaires  sur  les  évènements
cardiovasculaires  majeurs.  D’autres  facteurs  prenant  en  considération  les  préférences  indi-
viduelles,  les  comorbidités,  la  tolérance  des  médicaments  ou  encore  les  coûts  devraient  être
pris en  considération  lorsqu’une  des  deux  stratégies  est  retenue  dans  la  prise  de  ces  patients.
 Tou
f
a
w
i
f
p
A
a
m
a
M
S
A
u
C
t
e© 2011  Elsevier  Masson  SAS.
Introduction
AF  is  the  most  common  sustained  cardiac  arrhythmia.  Risk
factors  for  this  condition  include  male  sex,  smoking,  heart
failure,  diabetes,  arterial  hypertension,  left  ventricular
hypertrophy,  valvular  heart  disease,  myocardial  infarction
and  advanced  age.  The  lifetime  risk  of  developing  AF  in
subjects  aged  greater  than  40  years  is  around  25%  [1,2].
AF  is  associated  with  increased  cardiovascular  morbidity
and  mortality.  In  addition  to  the  deleterious  haemodynamic
effects  that  can  trigger  or  worsen  heart  failure,  AF  also
predisposes  to  thromboembolic  events;  stroke  incidence
increases  with  age,  with  the  5-year  risk  rising  from  1.5%  in
the  6th  decade  of  life  to  23.5%  in  those  aged  more  than  80
years  [3].  AF  is  an  independent  risk  factor  for  death  [4].
The  pharmacological  treatment  of  AF  follows  one  of  two
strategies:  rate  control  (controlling  the  ventricular  rate
with  beta-blockers,  non-dihydropyridine  calcium-channel
blockers  and/or  digitalis);  or  rhythm  control  (restoring
and  maintaining  sinus  rhythm  with  electrical  cardioversion
and/or  antiarrhythmic  agents)  [5].  Rhythm  control  mainte-
nance  with  antiarrhythmic  drugs  can  improve  symptoms  and
reduce  the  incidence  of  stroke  but  may  lead  to  an  increased
risk  of  adverse  events  due  to  negative  inotropic  and  proar-
rhythmic  effects  [6].  The  rate  control  strategy  may  have
s
u
bs  droits  réservés.
ewer  adverse  events  [7].  Antithrombotic  agents  are  usu-
lly  used  to  prevent  thromboembolic  events  in  association
ith  rate  control  drugs,  whereas  their  use  after  sinus  rhythm
s  restored  in  rhythm  control  depends  on  the  patient’s  risk
actors.
Our  aim  was  to  systematically  review  RCTs  and  com-
are  the  relative  effects  of  rate  and  rhythm  control  in
F.  We  proposed  to  analyse  clinically  relevant  outcomes:
ll-cause  mortality,  cardiovascular  mortality,  arrhyth-
ic/sudden  death,  ischaemic  stroke,  systemic  embolism
nd  major  bleeding.
ethods
earching
 search  strategy  was  developed  in  September  2011
sing  the  PubMed  and  Cochrane  Central  Register  of
ontrolled  Trials  (CENTRAL)  databases  for  study  iden-
iﬁcation.  There  were  no  language  limitations.  Refer-
nces  of  obtained  studies  were  also  comprehensively
earched.
The  electronic  search  for  RCT  publication  type  was
ndertaken  using  the  following  keywords:  rate,  beta-
locker,  acebutolol,  atenolol,  bisoprolol,  carvedilol,
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smolol,  metoprolol,  nadolol,  pindolol,  propranolol,  timo-
ol,  calcium-channel  blocker,  verapamil,  diltiazem,  digitalis,
igoxin,  rhythm,  amiodarone,  sotalol,  propafenone,  disopy-
amide,  dofetilide,  ﬂecainide,  ibutilide,  dronedarone  and
zimilide,  mortality,  death,  stroke,  embolism,  thromboem-
olic,  thromboembolism,  bleeding  and  atrial  ﬁbrillation.
oolean  operators  AND  and  OR  were  used  to  combine  terms.
ostoperative  and  postpercutaneous  intervention  studies
ere  excluded  from  the  search  using  the  Boolean  operator
OT.
election
e  included  RCTs  comparing  pharmacological  approaches
o  maintaining  rate  or  rhythm  control  in  patients  with  AF.
uasi-randomized  studies  and  prospective  cohorts  were  not
ncluded.  The  patients’  mean  age  had  to  be  greater  than
5  years  due  to  the  low  risk  of  death  or  stroke  in  patients
ith  AF  under  this  age  [4,8]. To  determine  the  efﬁcacy
f  the  interventions  as  primary  strategies,  the  trials  had
o  have  intention-to-treat  analysis  or  provide  data  that
llowed  this  type  of  calculation.  The  analysed  outcomes
ere  all-cause  mortality,  cardiovascular  mortality,  arrhyth-
ic/sudden  death,  ischaemic  stroke,  systemic  embolism
combining  ischaemic  stroke  and  other  systemic  embolic
vents)  and  major  bleeding.
alidity assessment
he  PEDro  score  was  used  to  assess  the  methodological  qual-
ty  of  data  reporting  in  the  studies  [9].  This  score  is  based
n  the  presence/absence  of  11  items:  eligibility  criteria,
andom  allocation,  allocation  concealment,  similar  baseline
haracteristics,  blinding  of  all  subjects,  blinding  of  ther-
pists,  blinding  of  outcome  assessors,  crossover  rate  less
han  15%,  intention-to  treat  analysis,  statistical  comparisons
etween  groups  and  measures  of  variability.
ata abstraction
tudies  that  met  the  criteria  outlined  above  were  assessed
y  one  review  author  and  checked  by  another.  AF
opulation,  study  size,  follow-up,  primary  outcome,  demo-
raphic  characteristics  and  comorbidities  were  retrieved.
nticoagulation  therapy,  and  rate  and  rhythm  interven-
ions  were  also  sought.  Data  entry  into  software  was
lso  double  checked.  All  disagreements  were  solved  by
onsensus.
uantitative data synthesis
he  statistical  analyses  were  performed  using  the  RevMan
oftware  (version  5.1.4)  provided  by  the  Cochrane  Col-
aboration  when  more  than  one  trial  had  data  for  pooled
nalysis.  Dichotomous  outcomes  were  analysed  by  the
antel-Haenszel  method.  RR  and  95%  CI  were  calculated.
hen  zero  cells  were  present  in  one  arm,  RevMan  automat-
cally  added  0.5  to  them  to  perform  the  calculations.  The
esults  estimates  were  based  on  a  ﬁxed-effects  model  or  a
andom  effects  model,  depending  on  heterogeneity.  Statis-
ical  heterogeneity  was  assumed  if  I2 was  greater  than  50%.
linical  heterogeneity  was  analysed  by  authors  according  to
w
0
t
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linical  differences  between  study  patients.  Publication  bias
ssessment  with  a  funnel  plot  was  planned  if  more  than  10
tudies  were  retrieved.
Sensitivity  analysis  was  planned  according  to  baseline
eart  failure,  age,  anticoagulation  treatment,  mean  follow-
p  and  study  size.
esults
ne  hundred  and  ﬁfty-seven  studies  were  found  in  the
atabase  search  and  146  studies  were  excluded:  11  were
ot  RCTs;  36  were  not  AF  studies;  73  citations  reported  tri-
ls  that  did  not  compare  pharmacological  rate  versus  rhythm
ontrol  in  AF;  and  26  records  were  substudies  of  eligible  tri-
ls.  Eleven  RCTs  remained  and  three  were  excluded  due  to
ack  of  data  necessary  for  analysis  based  on  intention-to-
reat.
Eight  RCTs  were  included  for  meta-analysis  [10—17]. Data
ot  provided  in  the  main  papers  were  sought  from  the  RACE
nd  AFFIRM  post-hoc  studies  (Fig.  1)  [18,19].
Included  studies  enrolled  a  total  of  7499  AF  patients  with
 mean  age  of  68  years.  In  all  these  trials  the  majority  of
atients  were  men  (63.4—82.0%).  Prevalence  of  hyperten-
ion  ranged  from  42.8  to  64.3%,  valvular  disease  from  4.9
o  17%  and  coronary  disease  from  7.4%  to  43.5%.  The  AF-
HF  study  and  the  CAFÉ-II  study  included  only  heart  failure
atients.  The  PIAF  study  provided  no  heart  failure  data.  In
he  other  trials,  the  prevalence  of  heart  failure  ranged  from
.6  to  70%.  Weighted  mean  follow-up  was  2.9  years,  ranging
rom  1  year  (PIAF)  to  3.5  years  (AFFIRM).
The  PEDro  quality  score  (scale  range  1—11)  for  the
btained  trials  varied  between  6  and  7.  None  of  the  trials
escribed  allocation  concealment  methods  and  interven-
ions  were  unblinded  for  patients  and  physicians.  The  RACE
tudy  was  the  only  one  that  reported  blinding  of  the
esearchers  who  recorded  the  outcomes.  The  PIAF  and  RACE
tudies  had  differences  in  relevant  baseline  characteris-
ics.  The  AFFIRM  and  AF-CHF  studies  and  the  J-RHYTHM
ad  crossover  rates  greater  than  15%.  Table  1  details  the
ain  characteristics  of  each  study  and  Table  2 contains  their
onclusions.
Rate  and  rhythm  control  showed  no  statistical  hetero-
eneity  in  any  outcome.  The  I2 test  was  0%  for  all  outcomes,
ith  the  exception  of  ischaemic  stroke,  which  reported  an
2 of  26%.  However,  the  authors  stated  that  the  existence  of
linical  heterogeneity  was  due  to  differences  in  the  patients
ncluded  in  the  studies.  The  different  types  of  AF  (paroxys-
al  and  persistent),  the  existence  of  studies  that  included
eart  failure  patients  exclusively  and  the  different  thera-
eutic  combinations/sequences  used  in  the  rate  and  rhythm
ontrol  strategies  led  us  to  choose  the  random  effects  model
or  pooled  analysis.  A  funnel  plot  for  publication  bias  analy-
is  was  not  done  because  it  is  not  recommended  when  fewer
han  10  studies  are  analysed  [20].
All-cause  mortality  was  assessed  in  all  trials  and  no
ntervention  showed  signiﬁcant  superiority  in  any  individ-
al  study.  To  determine  the  overall  effect,  a  meta-analysis
as  done  and  the  calculated  death  RR  was  0.95  (95%  CI:
.86—1.05)  (Fig.  2).  In  six  trials  with  a  total  of  6615  patients,
he  cardiovascular  mortality  RR  was  0.99  (95%  CI:  0.87—1.13)
Fig.  3).
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Table  1 Main  study  characteristics.
PIAF  [11]  RACE  [16,18]  AFFIRM
[17,19]
STAF  [10]  HOT  CAFÉ  [13]  AF-CHF  [14]  J-RHYTHM  [12]  CAFÉ-II  [15]
AF  population New-onset  AF
present
for  ≥  7  days
and  <  1  year
Recurrent  and
persistent  AF
or ﬂutter
for  <  1  year
Likely  to  be
recurrent  AF
in  pts
aged  >  65
years  with  risk
factors  for
stroke  or
death
Recurrent  and
persistent  AF
present  for  ≥  4
weeks  and  <  2
years
with  ≥  1  previous
cardioversion
AF present
for  ≥  7  days
and  <  2  years
LVEF  ≤  35%,
symptoms  of
CHF  and
history  of
paroxysmal  or
persistent  AF
for <  1  year
Paroxysmal
and  persistent
AF for  <  1  year
Persistent  AF
with  chronic
HF  and
NYHA  ≥  II
No.  of  pts 252 522 4060 200 205 1376 823 61
Mean  age  (SD) 61  (10) 68  (9) 70  (9) 66  (9) 61  (11) 67 64.8  (11) 72  (7)
Men  (%) 73 63.4 60.7 63.5 65.4 82 69.3 84
Hypertension
(%)
48.8 50 50.8 62.5 64.3 48 42.8 70
Valvular
disease  (%)
16.2 17 4.9 13 15.1 5 5.6 N/A
HF  (%) N/A 50 23.1 55.5
(NYHA  ≥  II)
70 100 3.6 100
CHD  (%) 23.4 27 26.1 43.5 43.9 48 7.4 50
Recommended
anticoagula-
tion
All  pts  antico-
agulated  (INR
2—3)
Acenocoumarol
or
fenprocoumon
4 weeks  before
and  after
electrical
cardioversion.
Rate  arm  anti-
coagulated  if
age  >  65  years
or  cardiac
disease
Both arms
anticoagu-
lated;  if  sinus
rhythm
restored  after
4  to  12  weeks
with
antiarrhythmic
agents,  anti-
coagulation
could  be
stopped
ACCP
guidelines
ACCP
guidelines
Recommended
for all  pts:
ACC/AHA/ESC
2006  AF
guidelines
Modiﬁed
AFFIRM
protocol  for
non-valvular
AF;  Japanese
guidelines  on
AF
management
for  valvular  AF
Recommended
for  all  pts:
warfarin  (INR
2—3)
Anticoagulated
pts:  rate  vs
rhythm  (%)
N/A 96  vs  86 >  85  vs  70 N/A 74.3  vs  15.6 90  pts
received  oral
anticoagulant
59.4 vs  60.1 98
230
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Table  1  (Continued)
PIAF  [11]  RACE  [16,18]  AFFIRM
[17,19]
STAF  [10]  HOT  CAFÉ  [13]  AF-CHF  [14]  J-RHYTHM  [12]  CAFÉ-II  [15]
Rate
intervention
Diltiazem  as
initial  drug
Digitalis,  non-
dihydropyridine
calcium-
channel
blocker  and
beta-blocker
Beta-blocker,
non-
dihydropyridine
calcium-
channel
blocker  and
digoxin
Beta-blocker,
digitalis  and
calcium-
channel
blocker;  AV
nodal  ablation
or  modiﬁca-
tion  ±  pacemaker
Beta-blocker,
non-
dihydropyridine
calcium-
channel
blocker  and
digoxin;
cardioversion
or  AV  nodal
ablation  and
pacemaker
Beta-blocker
and digoxin;
AV  nodal
ablation  and
pacemaker
Beta-blocker,
calcium-
channel
blocker  or
digitalis
Digoxin  and
beta-blocker
Beta-blocker
in  rate
control  (%)
N/A  41  68.1  N/A  89.1  N/A  51.5  90
Rhythm
intervention
Amiodarone  or
electrical
cardioversion
followed  by
amiodarone
Electrical
cardioversion
and sotalol,
ﬂecainide,
propafenone
or  amiodarone
Many
antiarrhythmic
agents  and/or
electrical
cardioversion
Electrical
cardioversion
and  class  I
antiarrhythmic
agents  or
sotalol;  CHD
or  LV
dysfunction,
amiodarone
Electrical
cardioversion
and
disopyramide,
propafenone,
sotalol  or
amiodarone
Electrical
cardioversion
and
amiodarone
(or sotalol  or
dofetilide)
Electrical
cardioversion
and
antiarrhythmic
agents
(pilsicainide,
cibenzoline,
propafenone,
disopyramide)
Amiodarone
and electrical
cardioversion
Amiodarone  in
rhythm
control  (%)
100 N/A  62.8  42  56.7  82  0.5  80
Mean  years  of
follow-up
(SD)
1  2.3  (0.6)  3.5  1.6  (0.7)  1.7  (0.4)  3.1  (1.6)  1.58  1.2a
PEDro  score  6  7  6  7  7  6  6  7
ACC: American College of Cardiology; ACCP: American College of Chest Physicians; AF: atrial ﬁbrillation; AFFIRM: Atrial Fibrillation Follow-up Investigation of Rhythm Management study;
AF-CHF: Atrial Fibrillation and Congestive Heart Failure study; AHA: American Heart Association; AV: atrioventricular; CAFÉ-II: controlled study of rate versus rhythm control in patients
with chronic AF and HF; CHD: coronary heart disease; CHF: congestive heart failure; ESC: European Society of Cardiology; HF: heart failure; HOT CAFÉ: How to Treat Chronic Atrial
Fibrillation study; INR: international normalized ratio; J-RHYTHM: Japanese Rhythm Management Trial for Atrial Fibrillation; LV: left ventricular; LVEF: left ventricular ejection fraction;
NYHA: New York Heart Association; N/A: not available; PIAF: Pharmacological Intervention in Atrial Fibrillation study; pts: patients; RACE: Rate Control versus Electrical Cardioversion
for Persistent Atrial Fibrillation study; SD: standard deviation; STAF: Strategies of Treatment of Atrial Fibrillation study.
a Median.
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Table  2  Data  and  results  from  individual  studies.
Trial  Population  Rate
control  (n)
Rhythm
control  (n)
Primary  outcome  Conclusions
PIAF  New-onset  AF
present
for  ≥  7  days
and  <  1  year
125 127  Improvement  in
AF-related  symptoms
(palpitations  and
frequency  of  dyspnoea  or
dizziness)
No differences  in  primary
outcome  and  quality  of
life;  rhythm  control  better
in  exercise  tolerance
RACE  Recurrent
persistent  AF  or
ﬂutter  for  <  1  year
256  266  Composite  of
cardiovascular  death,
heart  failure,  embolism,
bleeding,  pacemaker
implantation  and  severe
adverse  effects  of  drugs
No  statistically  signiﬁcant
differences  in  primary
outcome;  rate  superior  to
rhythm  control  in  women
and  hypertensive
subgroups
AFFIRM  Likely  to  be
recurrent  AF  in
pts  aged  >  65
years  with  risk
factors  for  stroke
or death
2027  2033  All-cause  mortality  No  differences  in  primary
outcome;  rate  control
prevented  mortality  in
age  >  65  years,  coronary
artery  disease  and  no  HF
group[s?];  rate  control
also  better  at  reducing
hospitalization
STAF  Recurrent  and
persistent  AF
present
for >  4  weeks
and  <  2  years
with  ≥  1  previous
cardioversion
100 100  Composite  of  all-cause
mortality,  cerebrovascular
events,  embolism  and
cardiopulmonary
resuscitation
No primary  outcome
advantage  with  rate  or
rhythm  control;  quality  of
life  improved  in  two  topics
with  rhythm  control  and
ﬁve  topics  with  rate
control
HOT  CAFÉ  AF  present
for ≥  7  days
and  <  2  years
101  104  Composite  of  all-cause
mortality  and
thromboembolic  and
major  bleeding
complications
No signiﬁcant  differences
in  primary  outcome;
hospitalizations  lower  in
rate  control
AF-CHF  LVEF  ≤  35%,
symptoms  of  CHF
and  history  of
paroxysmal  or
persistent  AF
for <  1  year
694  682  Cardiovascular  death  Primary  outcome  similar
with  both  interventions;
hospitalizations  more
frequent  in  rhythm  control
J-RHYTHM  Paroxysmal  and
persistent  AF
for <  1  year
404  419  Composite  of  total
mortality,  symptomatic
cerebral  infarction,
systemic  embolism,  major
bleeding,  hospitalization
for  heart  failure  and
physical/psychological
disabilities
Rhythm  control  reduced
the  incidence  of  the
primary  outcome  and
improved  the  frequency  of
symptoms  score
CAFÉ-II  Persistent  AF
with  chronic  HF
and  NYHA  ≥  II
31 30  QoL  SF-36vII  at  1  year  Rhythm  control  improved
the  primary  outcome
AF: atrial ﬁbrillation; AFFIRM: Atrial Fibrillation Follow-up Investigation of Rhythm Management study; AF: atrial ﬁbrillation; AF-CHF:
Atrial Fibrillation and Congestive Heart Failure study; CAFÉ-II: controlled study of rate versus rhythm control in patients with chronic AF
and HF; CHF: congestive heart failure; HF: heart failure; HOT CAFÉ: How to Treat Chronic Atrial Fibrillation study; J-RHYTHM: Japanese
Rhythm Management Trial for Atrial Fibrillation; LVEF: left ventricular ejection fraction; NYHA: New York Heart Association class; PIAF:
Pharmacological Intervention in Atrial Fibrillation study; pts: patients; QoL SF-36vII: Quality of Life Short Form-36 version II; RACE: Rate
Control versus Electrical Cardioversion for Persistent Atrial Fibrillation study; STAF: Strategies of Treatment of Atrial Fibrillation study.
232  D.  Caldeira  et  al.
Figure 1. Flowchart of study selection for meta-analysis. AF: atrial ﬁbrillation; CENTRAL: Cochrane Central Register of Controlled Trials;
RCTs: randomized controlled trials.
Figure 2. Forest plot for all-cause mortality. AFFIRM: Atrial Fibrillation Follow-up Investigation of Rhythm Management study; AF-CHF:
Atrial Fibrillation and Congestive Heart Failure study; CAFÉ-II: controlled study of rate versus rhythm control in patients with chronic atrial
ﬁbrillation and heart failure; CI: conﬁdence interval; HOT CAFÉ: How to Treat Chronic Atrial Fibrillation study; J-RHYTHM: Japanese Rhythm
Management Trial for Atrial Fibrillation; M-H: Mantel-Haenszel; PIAF: Pharmacological Intervention in Atrial Fibrillation study; RACE: Rate
Control versus Electrical Cardioversion for Persistent Atrial Fibrillation study; STAF: Strategies of Treatment of Atrial Fibrillation study.
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Figure 3. Forest plot for cardiovascular mortality. AFFIRM: Atrial Fibrillation Follow-up Investigation of Rhythm Management study; AF-
CHF: Atrial Fibrillation and Congestive Heart Failure study; CAFÉ-II: controlled study of rate versus rhythm control in patients with chronic
atrial ﬁbrillation and heart failure; CI: conﬁdence interval; HOT CAFÉ: How to Treat Chronic Atrial Fibrillation study; M-H: Mantel-Haenszel;
CE: 
n stu
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s
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PPIAF: Pharmacological Intervention in Atrial Fibrillation study; RA
Fibrillation study; STAF: Strategies of Treatment of Atrial Fibrillatio
The  arrhythmic/sudden  death  RR  was  1.12  (95%  CI:
0.91—1.38)  among  6410  patients  in  ﬁve  studies  (Fig.  4).
Ischaemic  stroke  data  was  retrieved  from  four  trials  with
a  total  of  5288  patients,  with  a  pooled  analysis  RR  of  0.89
(95%  CI:  0.52—1.53)  (Fig.  5).  Six  trials  with  6062  patients
evaluated  systemic  embolism  (which  included  ischaemic
strokes  and  other  systemic  embolic  events)  and  the  RR
was  0.89  (95%  CI:  0.69—1.14)  (Fig.  6).  Major  bleeding  also
showed  no  signiﬁcant  differences  in  results  pooled  from  ﬁve
RCTs  that  enrolled  5810  patients;  the  RR  was  1.10  (95%
q
p
a
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Figure 4. Forest plot for arrhythmic/sudden death mortality. AFFIRM:
study; AF-CHF: Atrial Fibrillation and Congestive Heart Failure study; CI:
Intervention in Atrial Fibrillation study; RACE: Rate Control versus Elec
Strategies of Treatment of Atrial Fibrillation study.Rate Control versus Electrical Cardioversion for Persistent Atrial
dy.
I:  0.89—1.36)  (Fig.  7).  Table  3  presents  a  summary  of  the
ndings.
A  sensitivity  analysis  was  done  according  to  variables
uch  as  heart  failure,  mean  age,  anticoagulation  treatment,
ean  follow-up  period  and  study  size,  as  shown  in  Table  4.
ooled  systemic  embolic  events  were  signiﬁcantly  less  fre-
uent  with  rate  control  when  trials  with  more  than  50%  of
atients  with  heart  failure  were  analysed.  The  PIAF,  AFFIRM
nd  J-RHYTHM  studies  were  excluded  for  this  reason.  The
R  was  0.43  (95%  CI:  0.21—0.89).
 Atrial Fibrillation Follow-up Investigation of Rhythm Management
 conﬁdence interval; M-H: Mantel-Haenszel; PIAF: Pharmacological
trical Cardioversion for Persistent Atrial Fibrillation study; STAF:
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Table  3  Summary  of  ﬁndings.
Outcome  Studies  Total
patients  (n)
Rate
control
patients  (n)
Rhythm
control
patients  (n)
Random
effects  (RR
[95%  CI])
Fixed-
effects  (RR
[95%  CI])
Heterogeneity
I2 (%)
All-cause
mortality
8 7499  3738  3761  0.95  [0.86—1.05] 0.94  [0.84—1.04] 0
Cardiovascular
mortality
7 6676 3334 3342 0.99  [0.87—1.13] 0.99  [0.87—1.13] 0
Arrhythmic/sudden
death
5  6410  3202  3208  1.12  [0.91—1.38] 1.12  [0.91—1.38] 0
Ischaemic
stroke
4  5288  2632  2656  0.89  [0.52—1.53] 0.92  [0.70—1.23] 26
Systemic
embolism
6  6062  3013  3049  0.89  [0.69—1.14] 0.88  [0.68—1.12] 0
Major  bleeding  5  5810  2888  2922  1.10  [0.89—1.36] 1.10  [0.89—1.36] 0
CI: conﬁdence interval; RR: risk ratio.
Table  4  Sensitivity  analysis.
Subgroup  Risk  ratio  [95%  CI]
Mortality Cardiovascular
mortality
Ischaemic  stroke  Systemic  embolism  Major  bleeding
≥  50%  of
patients
with  HF
[10,13—16]
1.04  [0.90—1.21] 0.97  [0.82—1.15] 0.18  [0.03—1.01]  0.43  [0.21—0.89]  1.01  [0.54—1.90]
Exclusively
patients
with  HF
[14,15]
1.03  [0.89—1.20] 0.95  [0.79—1.13] N/A  N/A  N/A
Mean  age  ≥  65
years
[10,14—17]
0.96  [0.85—1.08] 0.99  [0.87—1.13] 0.63  [0.16—2.49]  0.71  [0.40—1.26]  1.11  [0.89—1.37]
Mean  age  <  65
years
[11—13]
0.70  [0.25—2.00] 0.64  [0.12—3.27] 0.69  [0.10—4.78]  1.06  [0.52—2.18]  0.52  [0.05—5.70]
Recommended
anticoagula-
tion  for  all
patients
[11,14,15]
1.03  [0.89—1.20] 0.95  [0.79—1.13] N/A  N/A  N/A
Follow-
up  ≥  2  years
[14,16,17]
0.96  [0.83—1.10] 0.98  [0.86—1.12] N/A  0.74  [0.37—1.47]  1.14  [0.91—1.42]
<  200  patients
per  arm
[10,11,13,15]
1.25  [0.53—2.97] 1.63  [0.62—4.29] 0.18  [0.03—1.01]  0.52  [0.17—1.53]  0.73  [0.31—1.73]
≥  200  patients
per  arm
[12,14,16,17]
0.95  [0.86—1.05] 0.98  [0.86—1.12] 0.99  [0.74—1.33]  0.87  [0.57—1.34]  1.13  [0.91—1.41]
Excluding
AFFIRM  and
AF-CHF
1.13  [0.71—1.81] 1.19  [0.70—2.01] 0.50  [0.11—2.30]  0.70  [0.42—1.19]  0.97  [0.54—1.75]
AFFIRM: Atrial Fibrillation Follow-up Investigation of Rhythm Management study; AF-CHF: Atrial Fibrillation and Congestive Heart Failure
study; CI: conﬁdence interval; HF: heart failure; N/A: not available.
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Figure 5. Forest plot for ischaemic stroke. AFFIRM: Atrial Fibrillation Follow-up Investigation of Rhythm Management study; CI: conﬁdence
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cinterval; HOT CAFÉ: How to Treat Chronic Atrial Fibrillation study;
M-H: Mantel-Haenszel; STAF: Strategies of Treatment of Atrial Fibri
Discussion
This  systematic  review  with  meta-analysis  was  done  to
assess  the  direction,  size  and  consistency  of  effects
across  RCTs  comparing  rate  versus  rhythm  control  in
AF.
In  a  previous  meta-analysis,  rate  and  rhythm  control
strategies  were  not  signiﬁcantly  different  in  terms  of  mortal-
ity  but  a  trend  towards  rate  control  was  observed  in  patient
survival  (odds  ratio  0.87  [95%  CI:  0.74—1.02];  P  =  0.09)
[21].  Statistically  signiﬁcant  results  favouring  rate  control
with  regard  to  a  mortality-stroke  composite  have  been
reported  in  another  meta-analysis  (odds  ratio  0.84  [95%  CI:
d
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Figure 6. Forest plot for systemic embolism. AFFIRM: Atrial Fibrillatio
Atrial Fibrillation and Congestive Heart Failure study; CI: conﬁdence in
J-RHYTHM: Japanese Rhythm Management Trial for Atrial Fibrillation; M
Fibrillation study; RACE: Rate Control versus Electrical Cardioversion for
of Atrial Fibrillation study.YTHM: Japanese Rhythm Management Trial for Atrial Fibrillation;
n study.
.73—0.98];  P  =  0.02)  [22]. Under  these  circumstances  and
ith  new  RCTs,  it  is  important  to  clarify  which  is  the  best
reatment  strategy  according  to  the  best  available  evidence.
ur  meta-analysis  included  these  new  RCTs  and  provides
pdated  results  that  answer  with  more  powered  informa-
ion  whether  rate  or  rhythm  control  is  better  for  treating
hese  patients.
None  of  the  strategies  showed  superiority  in  the  out-
omes  assessed.  Although  the  results  of  individual  studies
id  not  show  clear  differences,  the  performance  of  the
eta-analysis  ensured  the  consistency  of  ﬁndings  for  a  large
opulation,  especially  when  approaching  very  important
linical  outcomes.
n Follow-up Investigation of Rhythm Management study; AF-CHF:
terval; HOT CAFÉ: How to Treat Chronic Atrial Fibrillation study;
-H: Mantel-Haenszel; PIAF: Pharmacological Intervention in Atrial
 Persistent Atrial Fibrillation study; STAF: Strategies of Treatment
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Figure 7. Forest plot for major bleeding. AFFIRM: Atrial Fibrillation Follow-up Investigation of Rhythm Management study; CI: conﬁdence
interval; HOT CAFÉ: How to Treat Chronic Atrial Fibrillation study; J-RHYTHM: Japanese Rhythm Management Trial for Atrial Fibrillation; M-
H: Mantel-Haenszel; RACE: Rate Control versus Electrical Cardioversion for Persistent Atrial Fibrillation study; STAF: Strategies of Treatment
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Despite  the  cardiovascular  consequences  of  AF,  we
onsidered  it  important  to  assess  all-cause  mortality  to
nclude  possible  non-cardiovascular  deaths  caused  by  antiar-
hythmic  drugs.  Amiodarone,  which  can  induce  pulmonary
oxicity,  was  prescribed  to  most  patients  in  four  of  the
ix  trials  that  reported  data  on  antiarrhythmic  agent  use
Table  1).  In  the  AFFIRM  analysis  of  cause-speciﬁc  mortality,
on-cardiovascular  deaths  were  mainly  due  to  pulmonary
iseases  and  lung  cancer.  Pneumonia  was  the  most  common
ause  of  pulmonary  death  in  both  interventions.  Pulmonary
oxicity  of  amiodarone  was  the  cause  of  death  in  only  three
f  39  patients  in  the  rhythm  intervention  who  died  due  to
ung  diseases  [19]. The  incidence  of  this  effect  may  be  more
mportant,  as  AF  needs  to  be  treated  longer  than  the  mean
ollow-up  of  this  study  and  the  long-term  incidence  of  amio-
arone  toxicity  events  is  likely  to  be  higher.
Cardiovascular  mortality  was  63%  of  the  total  mortality
f  all  trials  and  the  incidence  of  this  outcome  was  shown
o  be  independent  of  the  intervention  strategy.  In  AFFIRM,
rrhythmias  were  the  main  cause  of  cardiovascular  mortal-
ty,  probably  due  to  the  high  incidence  of  atherosclerotic
isk  factors  and  ischaemic  heart  disease  in  patients  with  AF
19,23].  In  a  post-hoc  analysis  of  the  RACE  trial,  myocar-
ial  infarction  history  was  the  baseline  characteristic  more
requently  associated  with  sudden  deaths  [18]. The  two
herapeutic  strategies  were  not  signiﬁcantly  different  with
egard  to  arrhythmic/sudden  death,  although  there  was  a
light  tendency  favouring  rhythm  control;  this  was  surprising
ecause  beta-blockers  (used  in  41%  and  68.1%  of  RACE  and
FFIRM  rate  control  patients,  respectively)  have  been  shown
o  prevent  sudden  death  in  patients  with  previous  myocar-
ial  infarction  [24]. Nevertheless,  AF  subgroup  analysis  of
he  US  Carvedilol  Heart  Failure  Trials  Program  showed  that
hese  drugs  had  no  advantage  in  reducing  mortality  in  these
atients  [25]. Antiarrhythmics  used  to  restore  and  maintain
inus  rhythm  have  been  shown  previously  to  be  ineffective
n  sudden  death  prevention  [26,27].  However,  an  increase  in
c
M
p
trrhythmic/sudden  death  adverse  effect  was  not  observed
nd  a  trend  towards  rhythm  control  preventing  this  outcome
as  seen.
AF  itself  can  be  considered  as  a prothrombotic  state  and
umulative  thrombotic  risk  factors  play  an  important  role
n  these  patients  [28,29]. Rate  control  groups  had  protocols
hat  favoured  the  maintenance  of  anticoagulant  therapy.  At
he  end  of  all  studies,  with  exception  of  J-RHYTHM,  the
hythm  control  group  had  fewer  anticoagulated  patients
han  the  rate  control  sample.  Recurrence  of  AF  and  anti-
oagulation  withdrawal  may  explain  the  trend  favouring
ate  control  in  ischaemic  stroke  and  systemic  embolism  out-
omes.  Vitamin  K  antagonists  were  the  chosen  drugs  for
nticoagulation.  These  drugs  have  a  narrow  therapeutic  win-
ow  with  major  bleeding  incidence  rates  ranging  from  1.4  to
3  per  100  patient-years  [30]. Major  bleeding  incidence  was
ot  different  between  the  interventions  but  there  was  a  ten-
ency  favouring  rhythm  control;  this  was  expected  because
nticoagulant  therapy  is  a  well-known  risk  factor  for  bleed-
ng  and  rate  control  patients  were  more  frequently  treated
ith  anticoagulants.
Sensitivity  analysis  showed  that  rate  control  was  better
t  preventing  embolic  events  in  a  pooled  analysis  of  stud-
es  with  more  than  50%  of  patients  with  heart  failure.  Heart
ailure  is  a  component  of  the  CHADS2 score  and  adequate
nticoagulation  may  have  produced  this  result  favouring
ate  control.  A  pooled  analysis  of  results  from  the  HOT  CAFÉ,
TAF  and  RACE  studies  was  done.  None  of  these  trials  had
oth  arms  anticoagulated  during  study  follow-up.  In  these
tudies,  rhythm  control  patients  were  less  likely  to  receive
ral  anticoagulation.  As  AF  may  have  a  structural  origin  and
rrhythmia  recurrence  is  frequent,  premature  or  inadequate
ithdrawal  of  oral  anticoagulants  in  the  rhythm  control  arm
ould  have  predisposed  towards  thromboembolic  events.
ore  recently,  AF-CHF,  an  RCT  that  exclusively  analysed
atients  with  heart  failure  with  both  rate  and  rhythm  con-
rol  arms  under  anticoagulation,  showed  that  stroke  was
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similar  between  interventions  (hazard  ratio  0.74  [95%  CI:
0.40—1.35]).
Eight  RCTs  were  included  in  the  meta-analysis,  but  most
of  the  statistical  weight  came  from  AFFIRM  and  AF-CHF.  A
sensitivity  analysis  excluding  these  trials  was  done.  A  pooled
analysis  of  the  smaller  studies  showed  the  same  result  as  the
primary  analysis  (Table  4).  It  is  interesting  that  when  trials
with  a  mean  patient  age  less  than  65  years  were  analysed,
there  was  a  trend  towards  rate  control.  The  analysed  popu-
lation  may  not  be  sufﬁciently  young  to  be  representative
of  younger/middle-aged  symptomatic  patients,  for  whom
the  primary  policy  would  be  to  restore  and  maintain  sinus
rhythm.
In  the  absence  of  a  clear  beneﬁt  for  one  intervention  in
the  analysed  outcomes,  other  factors  should  be  considered
for  strategy  choice,  such  as  individual  preferences,  comor-
bidities,  drug  tolerance  and  cost  issues;  regarding  this  last
factor,  cost-effectiveness  studies  favoured  the  rate  control
strategy  [31—33].
Implications for clinical practice and research
All-cause  mortality  and  cardiovascular  mortality  analysis
showed  no  trend  towards  either  intervention  and  had  small
CIs.  In  the  other  outcomes,  with  larger  CIs,  there  was  a
tendency  for  rate  control  to  be  better  in  the  prevention
of  ischaemic  stroke  and  systemic  embolism,  while  preven-
tion  of  arrhythmic/sudden  death  and  major  bleeding  tended
towards  rhythm  control.  These  last  data  were  not  statisti-
cally  signiﬁcant  but  can  be  clinically  relevant  when  applied
to  the  individual  patient,  tailoring  the  approach  according
to  their  characteristics.
Limitations
This  review  includes  a  meta-analysis  of  RCTs.  Results  were
pooled  from  reported  outcomes  and  not  from  individual
patient  data,  which  is  a  potential  source  of  bias  in  this  type
of  analysis.
Heterogeneity  of  clinical  characteristics  and  interven-
tions  across  the  various  studies  are  important  limitations
despite  the  random  effects  method  used  in  quantitative
analysis.
All  RCTs  included  in  this  meta-analysis  were  unblinded.
This  may  be  explained  by  the  physical  nature  of  electrical
cardioversion  that  is  very  distinct  from  rate  control  stan-
dard  procedures.  The  use  of  fake  electrical  cardioversion  for
blinding  would  raise  ethical  issues  and  would  interfere  with
other  outcomes  measured  in  some  studies,  such  as  quality
of  life  and  number  of  hospitalizations.
In  the  arrhythmic/sudden  death  outcome,  we  included
presumable  arrhythmic  deaths  from  AF-CHF,  arrhythmic
deaths  from  AFFIRM  and  sudden  deaths  from  the  other  trials.
For  studies  that  did  not  supply  data  for  systemic
embolism,  the  information  was  calculated  by  adding
ischaemic  stroke  to  systemic  embolism.  Ischaemic  stroke
can  be  either  embolic  or  thrombotic  but  most  ischaemic
strokes  in  AF  patients  have  a  cardiac  embolic  source
[34].
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onclusion
n  this  review,  rate  and  rhythm  control  options  did  not
iffer  in  terms  of  all-cause  mortality,  cardiovascular  mor-
ality,  arrhythmic/sudden  death,  ischaemic  stroke,  systemic
mbolism  and  major  bleeding.  The  large  population  of
atients  with  AF  from  which  quantitative  data  was  obtained
llowed  us  to  robustly  reinforce  the  conclusions  that  rate
nd  rhythm  control  are  similar  in  terms  of  clinical  outcomes.
his  supports  guidelines’  class  I  recommendations  for  rate
nd  rhythm  control  strategies  [35,36]. Both  are  acceptable
lternatives  for  patients  with  AF  and  the  initial  clinical
hoice  should  be  individualized  according  to  patient  pref-
rences,  AF  symptoms,  AF  recurrence  risk,  comorbidities,
olerance  to  antiarrhythmic  drugs  and  expected  costs.
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